ClinicalTrials.gg
CompletedNCT06602466Updated Jan 22, 2026Results posted

A Clinical Study Investigating the Effect of an Experimental Toothpaste Containing Stannous Fluoride in Improving Gingival Health

An interventional study of Test toothpaste and Colgate Cavity Protection Toothpaste in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this 4-week clinical study is to evaluate the ability of an experimental toothpaste, containing 0.454 percent (%) Stannous Fluoride (SnF2), 0.3% Zinc Chloride (ZnCl2) and 1% Alumina, to improve gingival health and plaque accumulation compared to a regular fluoride toothpaste (negative control) in participants with plaque-induced mild to moderate gingivitis.

Read the detailed description

This will be a single-center, 4 weeks, randomized, controlled, examiner-blind, 2 treatment arms, stratified, parallel group design clinical study, investigating gingival health and supra-gingival plaque reduction on healthy participants after using an experimental toothpaste containing 0.454% SnF2, 0.3% ZnCl2 and 1% Alumina. Sufficient participants will be screened so that at least 160 participants are randomized (approximately 80 per group) to ensure approximately 144 (approximately 72 per group) evaluable participants complete the entire study.

02

Conditions studied

  • Dental Plaque
  • Gingivitis
03

In context

Dental Plaque

354 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

This study's enrollment of 175 is above the median of 55 across 317 interventional studies indexed under Dental Plaque.

Browse Dental Plaque studies →

Lead sponsor

HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of a signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Biological sex at birth was male or female.
  • Aged 18 to 70 years inclusive, at the signing of the informed consent.
  • Willing and able to comply with scheduled visits, treatment plan, saliva sample collection, study restrictions, Lifestyle Considerations and other study procedures.
  • In good general and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
  • Participant oral health that meets all the following:

At Screening (Visit 1):

  • Participant with at least 20 natural, permanent teeth, (excluding 3rd molars).
  • Participant with at least 40 evaluable surfaces for MGI, BI, and TPI.
  • A healthy participant with mild to moderate plaque-induced gingivitis in the opinion of the clinical examiner.
  • Overall MGI less than or equal to (\<=) 1.75 to \<= 2.30

At Baseline (Visit 2):

  • Overall MGI greater than or equal to (>=) 1.75 to \<= 2.30
  • Overall TPI score >= 1.5

Exclusion criteria

Exclusion Criteria:

  • An employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator (or medically qualified designee), an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant who has any other clinical serious or unstable conditions (for example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) which could have affected study outcomes and/or participant safety.
  • A participant who is pregnant (self-reported) or intending to become pregnant over the duration of the study.
  • A participant who is breastfeeding.
  • A participant with known or suspected intolerance or to any study materials (or closely related compounds) or any of their stated ingredients.
  • A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol.
  • A participant who is a current smoker or an ex-smoker (including vaper) who stopped within 6 months of Screening.
  • A participant who is using smokeless forms of tobacco (for example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).
  • A participant who is diagnosed xerostomia or is taking any medication that in the view of the investigator is causing xerostomia.
  • A participant who has a medical condition which could have directly influenced gingival bleeding.
  • A participant who has a bleeding disorder that could have affected study outcomes and/or participant safety.
  • A participant who has a recent history (within the last year) of alcohol or other substance abuse.
  • A participant who has a severe oral condition (for example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  • Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
  • Medications exclusions: At Screening (Visit 1):

    1. A participant using any antibiotic medication within 28 days prior to screening or at any time during the study.
    2. Participant who has used an anti-bacterial toothpaste/mouthwash (for example, chlorhexidine) or another oral care product within 2 weeks of Screening that, in the opinion of the investigator or dentally qualified designee, could affect gingival health, plaque formation or oral bacteria.
    3. A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
    4. A participant currently taking a systemic medication (for example, anti-inflammatory, anticoagulant, ) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (for example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers, statins).
  • Medications exclusions: At Baseline (Visit 2):

    1. A participant who has taken any antibiotics during the (between Screening and Baseline).
    2. A participant who has taken (in the previous 14 days) a systemic medication (for example, anti-inflammatory, anti-coagulant, immunosuppressants) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (for example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
    3. A participant who has used an antibacterial dentifrice or mouthwash (for example, chlorhexidine) or any oral care product that in the view of the investigator could interfere with gingival health, plaque formation and oral bacteria, in the period between Screening and the Baseline visit.
  • Periodontal exclusions:

    1. A participant who shows signs of periodontitis [at both Screening (Visit 1) and Baseline visits (Visit 2)].
    2. A participant with a Basic Periodontal Examination (BPE) score of 4 or above in one or more sextants.
    3. A participant with BPE score >= 3, if with probing pocket, a single tooth dept is >= 5 mm.
    4. A participant who is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.
    5. A participant who has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.
  • Dental Exclusions:

    1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    2. A participant who has dentures (partial or full).
    3. A participant who has an orthodontic appliance (bands, appliances, or fixed/ removable retainers).
    4. A participant who received orthodontic therapy within 3 months of Screening.
    5. A participant who has numerous restorations in a poor state of repair.
    6. A participant who has any dental condition (for example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    7. A participant who has had dental prophylaxis within 12 weeks of Screening.
    8. A participant who has had teeth bleaching within 12 weeks of Screening.
    9. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.
  • A participant who has previously been enrolled in this study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Test Toothpaste

    Participants will brush their teeth with full ribbon of test toothpaste on head of toothbrush for one timed minute twice a day (morning and evening) for 4 weeks.

    Drug: Test toothpaste

  • Active comparator
    Reference Toothpaste (Negative Control)

    Participants will brush their teeth with full ribbon of reference toothpaste (Colgate Cavity Protection) on head of toothbrush for one timed minute twice a day (morning and evening) for 4 weeks.

    Drug: Colgate Cavity Protection Toothpaste

Interventions

  • DrugTest toothpaste

    0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.

  • DrugFluorophosphateStudies of FluorophosphateFluorophosphate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Commercial toothpaste containing 1450 ppm fluoride.

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Bleeding Index (BI) at Week 4

    The BI is an invasive assessment of gingival bleeding performed using a round-end probe. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. BI was assessed on 3-points scale ranging from 0 to 2, where 0= Absence of bleeding on probing, 1= Bleeding observed within 30 seconds of probing, 2= Bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.

    Time frame: Week 4

Secondary outcomes

  1. Adjusted Mean Number of Bleeding Sites (NBS) at Week 4

    The bleeding assessment was done using round-end probe. The number of bleeding sites for each participant= the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Adjusted mean value was derived using ANCOVA model.

    Time frame: Week 4

  2. Adjusted Mean Modified Gingival Index (MGI) at Week 4

    The MGI is a non-invasive visual assessment of gingival inflammation. MGI was assessed for all evaluable surfaces, four sites per tooth and was scored on a 5-point scale ranging from 0 to 4, where 0= Absence of inflammation, 4= Severe inflammation. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.

    Time frame: Week 4

  3. Adjusted Mean Overall Turesky Plaque Index (TPI) at Week 4

    The TPI is a non-invasive assessment of supra-gingival plaque accumulation. The plaque was disclosed using a plaque disclosing dye solution and the TPI was assessed using a 6-point scale ranging from 0 to 5, where 0= No plaque, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.

    Time frame: Week 4

  4. Adjusted Mean Interproximal TPI at Week 4

    The TPI is a non-invasive assessment of supra-gingival plaque accumulation. The plaque was disclosed using a plaque disclosing dye solution and the TPI was assessed using a 6-point scale ranging from 0 to 5, where 0= No plaque, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.

    Time frame: Week 4

07

Results

Posted Jan 22, 2026

Participant flow

This study was conducted at a single center in United Kingdom.

Participant flow — Overall Study
MilestoneTest ToothpasteReference Toothpaste (Negative Control)
Started8081
Completed7678
Not completed43
Withdrew: Adverse event20
Withdrew: Lost to follow-up13
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryAdjusted Mean Bleeding Index (BI) at Week 4

The BI is an invasive assessment of gingival bleeding performed using a round-end probe. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. BI was assessed on 3-points scale ranging from 0 to 2, where 0= Absence of bleeding on probing, 1= Bleeding observed within 30 seconds of probing, 2= Bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.

Time frame:
Week 4
Reported as:
Least squares mean · score on a scale
Adjusted Mean Bleeding Index (BI) at Week 4
score on a scaleTest ToothpasteReference Toothpaste (Negative Control)
Adjusted Mean Bleeding Index (BI) at Week 40.19 ± 0.0130.21 ± 0.013
Statistical analysis
  • Test Toothpaste vs Reference Toothpaste (Negative Control) · ANCOVA · p = 0.2992 · Adjusted mean difference: -0.02 · 95% CI -0.05 to 0.02
SecondaryAdjusted Mean Number of Bleeding Sites (NBS) at Week 4

The bleeding assessment was done using round-end probe. The number of bleeding sites for each participant= the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Adjusted mean value was derived using ANCOVA model.

Time frame:
Week 4
Reported as:
Least squares mean · bleeding sites
Adjusted Mean Number of Bleeding Sites (NBS) at Week 4
bleeding sitesTest ToothpasteReference Toothpaste (Negative Control)
Adjusted Mean Number of Bleeding Sites (NBS) at Week 430.0 ± 1.9632.5 ± 1.93
Statistical analysis
  • Test Toothpaste vs Reference Toothpaste (Negative Control) · ANCOVA · p = 0.3612 · Adjusted mean difference: -2.5 · 95% CI -7.9 to 2.9
SecondaryAdjusted Mean Modified Gingival Index (MGI) at Week 4

The MGI is a non-invasive visual assessment of gingival inflammation. MGI was assessed for all evaluable surfaces, four sites per tooth and was scored on a 5-point scale ranging from 0 to 4, where 0= Absence of inflammation, 4= Severe inflammation. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.

Time frame:
Week 4
Reported as:
Least squares mean · score on a scale
Adjusted Mean Modified Gingival Index (MGI) at Week 4
score on a scaleTest ToothpasteReference Toothpaste (Negative Control)
Adjusted Mean Modified Gingival Index (MGI) at Week 41.79 ± 0.0111.83 ± 0.010
Statistical analysis
  • Test Toothpaste vs Reference Toothpaste (Negative Control) · ANCOVA · p = 0.0117 · Adjusted mean difference: -0.04 · 95% CI -0.07 to -0.01
SecondaryAdjusted Mean Overall Turesky Plaque Index (TPI) at Week 4

The TPI is a non-invasive assessment of supra-gingival plaque accumulation. The plaque was disclosed using a plaque disclosing dye solution and the TPI was assessed using a 6-point scale ranging from 0 to 5, where 0= No plaque, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.

Time frame:
Week 4
Reported as:
Least squares mean · score on a scale
Adjusted Mean Overall Turesky Plaque Index (TPI) at Week 4
score on a scaleTest ToothpasteReference Toothpaste (Negative Control)
Adjusted Mean Overall Turesky Plaque Index (TPI) at Week 42.64 ± 0.0372.62 ± 0.036
Statistical analysis
  • Test Toothpaste vs Reference Toothpaste (Negative Control) · ANCOVA · p = 0.7616 · Adjusted mean difference: 0.02 · 95% CI -0.09 to 0.12
SecondaryAdjusted Mean Interproximal TPI at Week 4

The TPI is a non-invasive assessment of supra-gingival plaque accumulation. The plaque was disclosed using a plaque disclosing dye solution and the TPI was assessed using a 6-point scale ranging from 0 to 5, where 0= No plaque, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.

Time frame:
Week 4
Reported as:
Least squares mean · score on a scale
Adjusted Mean Interproximal TPI at Week 4
score on a scaleTest ToothpasteReference Toothpaste (Negative Control)
Adjusted Mean Interproximal TPI at Week 43.03 ± 0.0393.03 ± 0.038
Statistical analysis
  • Test Toothpaste vs Reference Toothpaste (Negative Control) · ANCOVA · p = 0.9321 · Adjusted mean difference: -0.00 · 95% CI -0.11 to 0.10

Adverse events

Collected over From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 69 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Toothpaste0/78 (0%)0/78 (0%)13/78 (16.7%)
Reference Toothpaste (Negative Control)0/83 (0%)0/83 (0%)6/83 (7.2%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTest ToothpasteReference Toothpaste (Negative Control)
ORAL MUCOSAL EXFOLIATIONGastrointestinal disorders4/782/83
HYPERAESTHESIA TEETHGastrointestinal disorders2/781/83
ORAL DISCOMFORTGastrointestinal disorders2/780/83
TONGUE ULCERATIONGastrointestinal disorders1/781/83
GINGIVAL PAINGastrointestinal disorders1/780/83
MOUTH ULCERATIONGastrointestinal disorders1/780/83
PARAESTHESIA ORALGastrointestinal disorders1/780/83
SALIVARY HYPERSECRETIONGastrointestinal disorders1/780/83
STOMATITISGastrointestinal disorders1/780/83
SWOLLEN TONGUEGastrointestinal disorders1/780/83

Baseline characteristics

Safety Population comprised of all randomized participants who received at least one dose of the investigational product. Post randomization, two participants (from test group) received incorrect study product (i.e. Reference product). The Safety Population is presented using actual study product received and thus, the Overall Number of Baseline Participants in "Reference Toothpaste (Negative Control)" is greater than the number of participants included in the Participant Flow module.

Age, Continuous
Age, Continuous(years)Test ToothpasteReference Toothpaste (Negative Control)Total
Mean27.0 ± 11.7527.9 ± 11.7627.5 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)Test ToothpasteReference Toothpaste (Negative Control)Total
Female444488
Male343973
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test ToothpasteReference Toothpaste (Negative Control)Total
Hispanic or Latino000
Not Hispanic or Latino7883161
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Test ToothpasteReference Toothpaste (Negative Control)Total
African American/African Heritage538
Asian - Central/South Asian Heritage262955
Asian - East Asian Heritage4610
Asian - South East Asian Heritage6612
White - Arabic/North African Heritage3710
White - White/Caucasian/European Heritage292857
Multiple549
08

Study locations

1 site
  • Birmingham University Dental School
    Birmingham, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Dec 2024, 2 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 2 months is close to that.

Counting every sponsor, half of 179 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Sep 23, 2024
Primary completionActual
Dec 13, 2024
CompletionActual
Dec 13, 2024
Results first posted
Jan 22, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06602466
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 23, 2024
Primary completion
Dec 13, 2024
Completion
Dec 13, 2024
Results posted
Jan 22, 2026
Last update
Jan 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion